In 2024 PHA Canada, in collaboration with PHA UK, conducted a survey to understand the perspectives of people with pulmonary arterial hypertension on clinical trials. Led by Dr. Jason Weatherald, this survey aimed to uncover the reasons behind patients' willingness or reluctance to participate in clinical trials.

The survey asked patients to comment on the impacts of pulmonary arterial hypertension on their lives, their experiences with clinical trials, and to share their opinions on a potential clinical trial on Sotatercept, a new treatment for PAH patients that was approved in Canada in 2024.

The findings guided researchers in designing patient-relevant trials with minimized participation burdens.

Your participation was invaluable in advancing pulmonary arterial hypertension research. We thank you for your time and for sharing your opinions with us.